Arrowhead Research | ARWR - Selling And Administration Expenses

Stock Price
63.59
Daily Change
-0.27 -0.42%
Monthly
-5.93%
Yearly
219.55%
Q1 Forecast
61.62

Arrowhead Research reported $46.02M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.31B 134M Sep/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xencor USD 87.78M 72.66M Sep/2025